Poster Home Next

Integrated Safety

  • Information
  • Resources

Integrated Safety icon

This poster reports on data of the safety of avacopan, C5a receptor inhibitor, from two Phase 2 and one Phase 3 studies in 439 patients with ANCA-associated vasculitis. Rates of exposure-adjusted total adverse event (AEs), serious AEs, withdrawal of study medication due to AEs, and pre-specified AEs of interest were calculated based on the integrated data from all three trials.

https://rheumnow.com/video-poster/safety-avacopan-anca-associated-vasculitis-combined-data-three-clinical-trials


Author(s):
  • Pirow Bekker, ChemoCentryx, Inc.
  • Peter A. Merkel, Division of Rheumatology, University of Pennsylvania
  • David R. W. Jayne, Department of Medicine, University of Cambridge


Display Label Action